Zacks: Analysts Anticipate Nektar Therapeutics (NASDAQ:NKTR) to Announce -$0.80 Earnings Per Share

Equities analysts expect Nektar Therapeutics (NASDAQ:NKTR) to report earnings per share of ($0.80) for the current quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Nektar Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.83) and the highest estimate coming in at ($0.73). Nektar Therapeutics posted earnings per share of ($0.61) during the same quarter last year, which would indicate a negative year over year growth rate of 31.1%. The firm is scheduled to issue its next quarterly earnings results on Thursday, November 4th.

According to Zacks, analysts expect that Nektar Therapeutics will report full-year earnings of ($3.02) per share for the current year, with EPS estimates ranging from ($3.17) to ($2.78). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.92) per share, with EPS estimates ranging from ($3.46) to $0.10. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Thursday, August 5th. The biopharmaceutical company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.03. The company had revenue of $28.33 million for the quarter, compared to analyst estimates of $26.42 million. Nektar Therapeutics had a negative return on equity of 45.74% and a negative net margin of 449.67%.

Several research firms recently issued reports on NKTR. SVB Leerink dropped their target price on Nektar Therapeutics from $20.00 to $19.00 and set a “market perform” rating on the stock in a report on Friday, August 6th. Bank of America began coverage on Nektar Therapeutics in a report on Friday, September 10th. They set a “neutral” rating and a $18.00 target price on the stock. Zacks Investment Research upgraded Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 target price on the stock in a report on Wednesday, August 4th. Finally, Stifel Nicolaus upgraded Nektar Therapeutics from a “hold” rating to a “buy” rating and upped their target price for the stock from $22.00 to $24.00 in a report on Monday, June 28th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $20.80.

Shares of Nektar Therapeutics stock traded down $0.01 during trading on Wednesday, reaching $16.50. The stock had a trading volume of 6,485 shares, compared to its average volume of 1,016,572. The company has a market capitalization of $3.03 billion, a price-to-earnings ratio of -6.28 and a beta of 1.46. The stock has a fifty day moving average price of $15.55 and a two-hundred day moving average price of $17.79. Nektar Therapeutics has a 52 week low of $12.92 and a 52 week high of $26.75.

In other news, SVP Mark Andrew Wilson sold 1,910 shares of the company’s stock in a transaction that occurred on Monday, August 16th. The stock was sold at an average price of $13.83, for a total value of $26,415.30. Following the transaction, the senior vice president now owns 200,915 shares of the company’s stock, valued at $2,778,654.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert Chess sold 3,524 shares of the company’s stock in a transaction that occurred on Wednesday, July 21st. The shares were sold at an average price of $16.81, for a total value of $59,238.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 53,817 shares of company stock worth $772,151. Company insiders own 2.91% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Vident Investment Advisory LLC grew its position in Nektar Therapeutics by 0.6% during the first quarter. Vident Investment Advisory LLC now owns 100,706 shares of the biopharmaceutical company’s stock worth $2,015,000 after buying an additional 632 shares in the last quarter. Nordea Investment Management AB grew its position in Nektar Therapeutics by 2.2% during the first quarter. Nordea Investment Management AB now owns 31,865 shares of the biopharmaceutical company’s stock worth $633,000 after buying an additional 685 shares in the last quarter. Virginia Retirement Systems ET AL grew its position in Nektar Therapeutics by 5.8% during the first quarter. Virginia Retirement Systems ET AL now owns 12,700 shares of the biopharmaceutical company’s stock worth $254,000 after buying an additional 700 shares in the last quarter. Grandfield & Dodd LLC grew its position in Nektar Therapeutics by 3.1% during the second quarter. Grandfield & Dodd LLC now owns 28,058 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 850 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in Nektar Therapeutics by 1.5% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 60,777 shares of the biopharmaceutical company’s stock worth $1,216,000 after buying an additional 869 shares in the last quarter. 90.59% of the stock is currently owned by institutional investors.

About Nektar Therapeutics

Nektar Therapeutics is a research-based biopharmaceutical company that focuses on discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and auto-immune disease.

Read More: Why does a company issue an IPO?

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.